Clinical Trial

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS≥1
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-21.
Status change: Not Yet Recruiting → Recruiting 2025-07-16
Trial Details
NCT Number NCT06793917
Lead Sponsor Fujian Cancer Hospital
Conditions Gastric Cancer
Enrollment 269 participants
Start Date 2025-06-07
Primary Completion 2028-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-20